DelveInsight’s “Pulmonary Embolism Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Pulmonary Embolism market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers the emerging Pulmonary Embolism drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Pulmonary Embolism treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Pulmonary Embolism: An Overview
Pulmonary embolism (PE) is a common and potentially deadly form of venous thromboembolic disease. A PE is a blockage within a pulmonary artery in the lungs. The most common cause of such a blockage is a blood clot that forms in a deep vein in the leg and travels to the lungs, where it gets lodged in a smaller lung artery. Almost all blood clots that cause PE are formed in the deep leg veins. Clots can also form in the deep veins of the arms or pelvis.
Half the people who have PE have no symptoms. If they do have symptoms, they can include shortness of breath, chest pain, or coughing up blood. Symptoms of a blood clot include warmth, swelling, pain, tenderness, and redness of the leg.
It is one of the most common causes of cardiovascular death and is associated with multiple inherited and acquired risk factors as well as advanced age. The populations at greatest risk of PE include those who had recent trauma, had recent major surgery, are obese, are pregnant, underwent hormonal therapy, smoke, and have certain cancers.
Pulmonary Embolism Market Key Facts
-
As per Chuang et al. (2017), the incidence rate of PE was estimated at 0.95 per 1000 in Europe.
-
Of the 2,454 patients with PE in International Cooperative Pulmonary Embolism Registry (ICOPER), 1,095 were men (45%) and 1,359 were women (55%).
-
As per the Office of the Surgeon General (US) and the National Heart Lung and Blood Institute (US) (2008), those who suffer from an initial episode of PE are estimated to have a 30% chance of recurrence in the next 10 years, with the greatest risk in the first 2 years
-
According to the Centers for Disease Control and Prevention (CDC) (2022), the precise number of people affected by deep vein thrombosis (DVT) or PE is unknown, although as many as 900,000 people could be affected each year in the US. One-third (about 33%) of people with DVT/PE have a recurrence within 10 years.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Pulmonary Embolism market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Pulmonary Embolism market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Pulmonary Embolism Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Pulmonary Embolism epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Pulmonary Embolism Epidemiology, Segmented as –
-
Total Incident cases of Pulmonary Embolism in the 7MM [2019–2032]
-
Gender-specific cases of Pulmonary Embolism in the 7MM [2019–2032]
-
Treated cases of Pulmonary Embolism in the 7MM [2019–2032]
-
Severity-specific cases of Pulmonary Embolism in the 7MM [2019–2032]
Pulmonary Embolism Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Pulmonary Embolism market or expected to be launched during the study period. The analysis covers the Pulmonary Embolism market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the Pulmonary Embolism market drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares Pulmonary Embolism drugs based on their sale and market share.
The report also covers the Pulmonary Embolism pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Pulmonary Embolism Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/pulmonary-embolism-market-insights
Pulmonary Embolism Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Pulmonary Embolisms. Currently, Supergene is leading the therapeutics market with its Pulmonary embolism drug candidates in the most advanced stage of clinical development.
Pulmonary Embolism Companies Actively Working in the Therapeutics Market Include
-
Translational Sciences
-
Supergene
-
Angde Biotech
-
Yuhan
And Many Others
Emerging and Marketed Pulmonary Embolism Therapies Covered in the Report Include:
Recombinant staphylokinase (Supergene): Recombinant staphylokinase contains Forteplase as the active substance. It is a single-chain molecule, consisting of 138 amino acids. When staphylokinase is added to human plasma containing a fibrin clot, it preferentially reacts with plasmin at the clot surface, forming a plasmin-staphylokinase complex. The drug is in Phase III clinical evaluation for the treatment of pulmonary embolism.
TS2 (Translational Sciences): TS2 is a first-in-class anti-α2-antiplasmin monoclonal antibody, which is being developed to dissolve thrombi that cause serious conditions such as PE and acute ischemic stroke (AIS).
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/pulmonary-embolism-market-insights
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Pulmonary Embolism Competitive Intelligence Analysis
4. Pulmonary Embolism Market Overview at a Glance
5. Pulmonary Embolism Disease Background and Overview
6. Pulmonary Embolism Patient Journey
7. Pulmonary Embolism Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Pulmonary Embolism Treatment Algorithm, Current Treatment, and Medical Practices
9. Pulmonary Embolism Unmet Needs
10. Key Endpoints of Pulmonary Embolism Treatment
11. Pulmonary Embolism Marketed Therapies
12. Pulmonary Embolism Emerging Drugs and Latest Therapeutic Advances
13. Pulmonary Embolism Seven Major Market Analysis
14. Attribute Analysis
15. Pulmonary Embolism Market Outlook (In US, EU5, and Japan)
16. Pulmonary Embolism Access and Reimbursement Overview
17. KOL Views on the Pulmonary Embolism Market
18. Pulmonary Embolism Market Drivers
19. Pulmonary Embolism Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/pulmonary-embolism-market-insights
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Chronic Idiopathic Constipation Market
“Chronic Idiopathic Constipation Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Chronic Idiopathic Constipation market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Chronic Idiopathic Constipation market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/